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In the nine years since the unexpected discovery of a second form of the estrogen receptor (ER), ERβ has
been mentioned in about 2,800 literature citations. Such prolific research is testimony to interest in explaining
its role in estrogen physiology as well as investigating its potential as a drug target. Our current understanding
is that ERα, not ERβ is responsible for mediating the effects of estrogens in “classic” model systems such
as the reproductive tract and skeleton.The role of ERβ is still being defined, but profiling of ERβ selective
agonists in several animal models of human disease indicates these compounds may have utility as novel
anti-inflammatory agents.The challenge for the future is to elucidate their mechanism of action and determine
the clinical relevance of the impressive preclinical observations.
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Introduction
I was not at the 1996 Keystone Symposium on Nuclear
Receptors where Jan-Åke Gustafsson unveiled the
existence of a second estrogen receptor (ER), ERβ, but
I do recall the excitement of the other scientists in our
group who attended and heard the news.
There were two primary reasons for the stir around this
newly discovered ER. First, it was unexpected and it was
intriguing to speculate about which aspects of estrogen
physiology were attributable to ERβ. In 1986 two groups
cloned the first ER [Green et al., 1986; Greene et al.,
1986], now called ERα, and in 1993 a knockout mouse
was created that had the severe expected phenotype
[Lubahn et al., 1993].The major actions of estrogens
seemed explained, so there was not a large effort to seek
other ERs.
The second reason for the excitement was the prospect
of developing new and medically useful compounds based
on selective interaction with ERβ. At the time of ERβ’s
discovery, estrogens were thought to positively influence
almost all bodily systems and postmenopausal hormone
therapy was prescribed for long-term use.These days,
with the results from the Women’s Health Initiative,
prescribing recommendations have changed, but it is
important to realize the environment that existed at the
time of ERβ’s discovery.
This perspective will describe our efforts in evaluating
and developing ERβ as a drug target and highlight some
lessons learned along the way (see Figure 1). Much of
this article is based on a presentation given at the 2005
Keystone Symposium on Tissue Selective Nuclear
Receptors.
Designing ERβ selective agonists: a
significant medicinal chemistry
challenge
The amino acid sequence of the ERβ ligand binding
domain is about 60% identical to that of ERα [Kuiper et
al., 1996].Thus, a 40% difference seemed sufficient to
allow for the design of selective small molecules.
However, among the amino acids that are close to the
ligand in the binding pocket, there are only two
conservative amino acid differences between ERα and
ERβ.While this finding initially discouraged the team, it
ultimately helped focus our synthetic chemistry efforts on
the regions of the pharmacophore best positioned to make
preferential interactions with ERβ [Manas et al., 2004]. A
number of ERβ selective agonists have been synthesized
(by our group and others; see [Veeneman, 2005] for
review), thus highlighting the ability to capitalize even on
very subtle sequence differences to gain selectivity.
Once significantly ERβ selective compounds were
synthesized, they were used as tools to probe ERβ
function. Interpretation of these studies was greatly aided
by the use of an ERα selective agonist, PPT [Harris et
al., 2002; Stauffer et al., 2000], which was designed by
John Katzenellenbogen’s group.
ERβ selective agonists are not classic
estrogens (both good and bad news)
From a drug discovery point of view, a key attribute for
ERβ was that it was not highly expressed in the uterus.
Happily, we found that reasonably selective agonists (>
~50-fold) were nonuterotrophic.We were also pleased
to find that our lead compounds did not stimulate
www.nursa.org  NRS  | 2006 |  Vol. 4 |  DOI: 10.1621/nrs.04012 | Page 1 of 4
Perspective  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1. A schematic of the evolution of the ERβ project within our group. Initial assumptions about the usefulness of ERβ selective agonists
in hormone therapy and contraception proved incorrect, leading to exploration of other possible utilities. Our current constellation of in vivo activities
all relate to inflammatory diseases, but the mechanism of action is unknown. Understanding the molecular processes influenced by this class of
compounds will undoubtedly allow us to learn more about the biology of ERβ.
mammary end bud development. However, we also
discovered that ERβ selective agonists did not inhibit
ovulation, prevent ovariectomy-induced vasomotor
instability or bone loss [Harris et al., 2003]. PPT, the ERα
selective agonist was as efficacious as estradiol on many
of these endpoints, suggesting that ERα stimulation is
both necessary and sufficient for the “classic” effects of
estrogens [Harris et al., 2002].Thus, although these data
predict lower clinical liability for an ERβ selective agonist,
they did not point us in the direction of potential
indications.
Looking beyond menopause and
contraception for an ERβ effect
Based on the data mentioned above, we quickly
abandoned looking for ERβ utility in the area of women’s
health and instead turned our attention to systems where
nonselective estrogens (e.g. 17β-estradiol) had effects.
This led us to examine the activity of our ERβ compounds
in inflammatory diseases. Several disease models have
been examined and four of these are summarized below.
Inflammatory bowel disease and arthritis
The HLA-B27 transgenic rat is a model of chronic
inflammation and develops several age-dependent
phenotypes.When given orally, both ERB-041 [Harris et
al., 2003] and WAY-202196 [Mewshaw et al., 2005]
rapidly reversed the chronic diarrhea these rats develop
after about 10 weeks of age. Concomitant improvements
were seen in intestinal histology with a reduction in lesions
as well as inflammatory cell infiltrates, and a return of
goblet cells.The minimum fully efficacious dose for these
compounds was ≤1mg/kg.
The HLA-B27 transgenic rats also develop arthropathy
as they age, and ERβ selective agonists prevented
[Mewshaw et al., 2005] and reversed (unpublished
observations) this joint swelling.This observation
prompted examination of compounds in a second model
of arthritis, Lewis rat adjuvant-induced arthritis. In this
model, arthritis is induced 8-9 days after an intradermal
injection of complete Freund’s adjuvant. Both ERB-041
and WAY-202196 rapidly reduced joint redness and
swelling, as well as synovitis and Mankin scores (scores
of histological joint damage). Furthermore, ERB-041
substantially normalized the majority of
disease-responsive mRNA changes in the liver, popliteal
lymph node and spleen, as well as those in the plasma
proteome [Follettie et al., 2006].
Endometriosis
Although it is counterintuitive to evaluate an estrogen
receptor agonist in an estrogen dependent disease, we
tested ERB-041 in an in vivo model of experimentally
induced endometriosis because endometriosis is an
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volunteers can establish endometrosis-like lesions when
implanted into nude mice [Grummer et al., 2001].When
administered after lesions have established, ERB-041
(10mg/kg) caused complete lesion regression in 40-75%
of the animals, depending on the study [Harris et al.,
2005]. Recovered lesions expressed ERα and no
detectable ERβ (regardless of the treatment the animal
received), thus ERB-041 would appear to act on the host,
not on the implanted tissue. Although nude mice lack T
cells, they have functional macrophages and natural killer
cells and thus ERB-041 may be stimulating the ability of
these cells to recognize the implanted tissue as foreign
and to clear it.
Sepsis
The logic for testing ERβ selective compounds in models
of systemic infection was that, because these compounds
were likely immunomodulators, we wanted to assess
whether they would be globally immunosuppressive
[Cristofaro et al., In Press]. It should be noted that we
tested high doses of compound because we were looking
for a potential deleterious effect. One model used intact
female rats rendered neutropenic and then given an oral
bolus of Pseudomonas aeruginosa.To our surprise, rats
treated orally with WAY-202196 (50mg/kg) on days 4-11
after Pseudomonas inoculation survived longer than rats
treated with vehicle (83% vs 25%). Moreover, intestinal
histology was significantly improved.
The second model of sepsis used controlled puncture of
the cecum in intact female mice to induce acute bacterial
peritonitis. Again, daily oral doses of WAY-202196
(50mg/kg) improved survival over mice treated with
vehicle (78% vs 0%) and intestinal histology was
improved.
Future directions
We have made great strides in developing tools to
evaluate ERβ function in vivo and have uncovered an
impressive array of activities in animal models of human
disease. Some of this testing was directed, but other
discoveries were made purely by serendipity. Currently
we are hampered by our lack of a mechanistic
understanding of how these compounds work. Defining
mechanism is difficult for several reasons. First, there are
a wide variety of potential target cells. Many types of
immune system cells express ERβ, as do cells of the
intestine and joint.Thus it is difficult to decide which cell
type to study in depth. Secondly, we have been unable
to translate our impressive in vivo activities into in vitro
systems. For example, our compounds do not influence
T cell proliferation in standard assays nor do they prevent
monocyte activation after stimulation with lectins, etc.
Thirdly, each in vivo activity may be explained by a
different mechanism; after all, ERβ is a transcription
factor. Finally, ERβ compounds seem to have minimal,
if any, effects in normal healthy animals.This has led to
postulation of a “challenge hypothesis”, which says that
a target cell or organ needs to be injured/stressed/or
otherwise compromised in order to respond to ERβ.While
this may be convenient therapeutically, it poses a
significant scientific challenge to determine mechanism
if one is restricted to using complex in vivo models.
It is also important to be aware that, although a number
of selective ERβ compounds have been designed, not
many have been widely tested in vivo. Moreover, since
only DPN [Meyers et al., 2001] is commercially available,
confirmation of published data by other groups is
problematic. Although our group’s ERβ selective
compounds from several different chemical series seem
to behave similarly and seem to be full agonists, they
may not elicit the full range of ERβ biology in vivo. Many
other scientists, both at academic and industrial
institutions, are exploring biological activities other than
those reported here (e.g. prostate proliferation, vasomotor
instability [Opas et al., 2006], anxiety/depression [Lund
et al., 2005;Walf and Frye, 2005], and subfertility
[Hegele-Hartung et al., 2004]). As a field, we need data
from a variety of sources to piece together the full
spectrum of ERβ activity.
The discovery of ERβ came at a time when powerful
scientific tools were readily available to try and understand
its contribution to estrogen physiology. Engineered mice,
structure-based drug design, and microarray analysis
were just a few of the state-of-the-art techniques that
were immediately brought to bear on this problem. And
while significant progress has been made, and indeed
compounds have been advanced into clinical trials to see
if data gathered from preclinical models will translate into
human disease, we are really just at the beginning of
understanding how this receptor functions.
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